Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5174723
Max Phase: Preclinical
Molecular Formula: C25H22ClN7O2
Molecular Weight: 487.95
Associated Items:
ID: ALA5174723
Max Phase: Preclinical
Molecular Formula: C25H22ClN7O2
Molecular Weight: 487.95
Associated Items:
Canonical SMILES: COc1ccc(-c2ccc3[nH]c(=O)c4nnn(-c5ccc(N6CCNCC6)c(Cl)c5)c4c3c2)cn1
Standard InChI: InChI=1S/C25H22ClN7O2/c1-35-22-7-3-16(14-28-22)15-2-5-20-18(12-15)24-23(25(34)29-20)30-31-33(24)17-4-6-21(19(26)13-17)32-10-8-27-9-11-32/h2-7,12-14,27H,8-11H2,1H3,(H,29,34)
Standard InChI Key: XUCKDROCCGFJIV-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 487.95 | Molecular Weight (Monoisotopic): 487.1524 | AlogP: 3.40 | #Rotatable Bonds: 4 |
Polar Surface Area: 100.96 | Molecular Species: BASE | HBA: 8 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 13.26 | CX Basic pKa: 8.85 | CX LogP: 3.79 | CX LogD: 2.34 |
Aromatic Rings: 5 | Heavy Atoms: 35 | QED Weighted: 0.40 | Np Likeness Score: -1.56 |
1. Ouyang Y, Si H, Zhu C, Zhong L, Ma H, Li Z, Xiong H, Liu T, Liu Z, Zhang Z, Zhang ZM, Cai Q.. (2022) Discovery of 8-(6-Methoxypyridin-3-yl)-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1,5-dihydro-4H-[1,2,3]triazolo[4,5-c]quinolin-4-one (CQ211) as a Highly Potent and Selective RIOK2 Inhibitor., 65 (11.0): [PMID:35584513] [10.1021/acs.jmedchem.2c00271] |
Source(1):